Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEP1B | Q16820 | 13/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | MEP1A | Q16819 | 3/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7090040 | 0.89 | MEP1B (0.43) | MEN1KMT2AMEP1BPPARGMEP1A | |
| SCHEMBL7083824 | 0.84 | PRSS1 (0.51) | MEN1KMT2APPARG | |
| SCHEMBL7087183 | 0.82 | MEN1 (0.54) | MEN1KMT2AMEP1BMEP1A | |
| SCHEMBL7083364 | 0.82 | GRIN2D (0.51) | MEP1BPPARGMEP1APTGES | |
| SCHEMBL7087160 | 0.81 | MEP1B (0.53) | MEN1KMT2AMEP1BPPARGMEP1A | |
| SCHEMBL7083688 | 0.80 | PPARG (0.52) | KMT2AMEP1BPPARGMEP1A | |
| SCHEMBL7087197 | 0.78 | HDAC1 (0.53) | MEP1BPPARGMEP1A | |
| SCHEMBL6448577 | 0.77 | NOS1 (0.44) | MEN1KMT2AMEP1BMEP1A | |
| SCHEMBL1701279 | 0.76 | KMT2A (0.76) | MEN1KMT2AATM | |
| SCHEMBL7083256 | 0.76 | HDAC1 (0.55) | MEP1BPPARGMEP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199698-A1 | Carbamic acid esters as inhibitors of factor xa | MERCK PATENT GMBH (DE) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199698-A1 | Carbamic acid esters as inhibitors of factor xa | F11, F12, F13A1 | MEN1 513/4885KMT2A 2403/4885MEP1B 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.